Epitranscriptomic Regulation of PIK3R2 by WTAP/YTHDF3 Axis Drives Nasopharyngeal Carcinoma Progression
Clinical and Experimental Pharmacology and Physiology · 2026-11 · 53 (11)
DOI: 10.1111/1440-1681.70163 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Pharmacology and Physiology, online erschienen am 13.11.2026. Verfasst von Yilong Xu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Quanzhou Maternity and Children's Hospital, Quanzhou City, Fujian Province, China. Hauptthemen laut MEDLINE: Cell Cycle Proteins, Nasopharyngeal Carcinoma, Phosphatidylinositol 3-Kinases, RNA Splicing Factors. Die Arbeit nennt 52 Literaturangaben. Gefördert von: Quanzhou City Science and Technology Project, 2024 Joint Innovation Project of Overseas Chinese University Medical College.
Abstract (Originalsprache)
Background
Nasopharyngeal carcinoma (NPC) is an aggressive malignancy with a distinct geographical distribution. Phosphoinositide‐3‐kinase regulatory subunit 2 (PIK3R2) has been identified as an oncogenic driver in various cancers. However, the role and regulation of PIK3R2 in NPC remain poorly understood.
Methods
Bioinformatics analysis of GSE61218 public dataset assessed PIK3R2 expression. Functional assays in NPC cell lines included proliferation (EdU assay), apoptosis (flow cytometry), migration/invasion (Transwell assay), and HUVEC tube formation ability (tube formation assay). Subcutaneous xenograft models evaluated tumour growth. The relationship between the WTAP/YTHDF3 axis and PIK3R2 was investigated using RNA immunoprecipitation (RIP), methylated RIP (MeRIP), mRNA stability assays, and rescue experiments.
Results
PIK3R2 was upregulated in NPC cell lines. Its knockdown suppressed the proliferation, migration, and invasion of NPC cells, impaired the tube‐forming capacity of HUVECs, and promoted cancer cell apoptosis in vitro, while also inhibiting tumour growth in vivo. Mechanistically, WTAP, a component of the m6A writer complex, and the reader YTHDF3 formed an axis that contributed to PIK3R2 mRNA stability in an m6A‐dependent manner. Re‐expression of PIK3R2 partially rescued oncogenic phenotypes in WTAP‐depleted NPC cells. Moreover, PIK3R2 re‐expression partially reversed in vivo tumour suppression by WTAP knockdown. Additionally, PIK3R2 knockdown reduced p85 (Tyr458) phosphorylation and AKT phosphorylation, while PIK3R2 re‐expression partially restored p85 and AKT phosphorylation in WTAP‐depleted cells.
Conclusion
This study identifies PIK3R2 as a novel oncogenic driver in NPC and reveals that its overexpression is orchestrated by the WTAP/YTHDF3‐mediated m6A modification axis. Our findings suggest that this regulatory pathway may represent a mechanistic axis worthy of further functional investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otorhinolaryngology, Quanzhou Maternity and Children's Hospital, Quanzhou City, Fujian Province, China.
- Department of Otolaryngology-Head and Neck Surgery, Quanzhou Maternity and Children's Hospital, Quanzhou City, Fujian Province, China.
ORCID-Profile: Mingyan Hong
Förderung
- Quanzhou City Science and Technology Project
- 2024 Joint Innovation Project of Overseas Chinese University Medical College
Zitieren
APA
Xu, Y., Xu, Y., Chen, Y., Lin, S., Liu, Y., Dai, S., & Hong, M. (2026). Epitranscriptomic Regulation of PIK3R2 by WTAP/YTHDF3 Axis Drives Nasopharyngeal Carcinoma Progression. Clinical and Experimental Pharmacology and Physiology, 53(11). https://doi.org/10.1111/1440-1681.70163
Vancouver
Xu Y, Xu Y, Chen Y, Lin S, Liu Y, Dai S, et al. Epitranscriptomic Regulation of PIK3R2 by WTAP/YTHDF3 Axis Drives Nasopharyngeal Carcinoma Progression. Clinical and Experimental Pharmacology and Physiology. 2026;53(11). doi:10.1111/1440-1681.70163
BibTeX
@article{Xu2026,
author = {Xu, Yilong and Xu, Yanyu and Chen, Yongqin and Lin, Shaorong and Liu, Yaxue and Dai, Sihai and Hong, Mingyan},
title = {Epitranscriptomic Regulation of PIK3R2 by WTAP/YTHDF3 Axis Drives Nasopharyngeal Carcinoma Progression},
journal = {Clinical and Experimental Pharmacology and Physiology},
year = {2026},
volume = {53},
number = {11},
doi = {10.1111/1440-1681.70163}
}
EUVIMED